Vascular Solutions, Inc. (NASDAQ: VASC) is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of three major categories: hemostat (blood clotting) products, catheter products and vein products. Vascular Solutions delivers its proprietary and distributed products to interventional cardiologists, interventional radiologists and vascular surgeons through its direct U.S. sales force and international distributor network.
Investor Relations Contact
To receive an investor information packet, complete the investor information request contact form.
For investor relations questions, contact Phil Nalbone, Vice President of Corporate Development at firstname.lastname@example.org, 763.656.4371.
To access SEC forms, including 10-K, 8-K, 10-Q, Form 5, Form 4 and others, click on the “SEC Filings” link to the left.
Stock Exchange Listing
Our stock trades on the NASDAQ National Market under the symbol VASC.
“Forward Looking Statements” The information in (or directly accessible from) this website contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, exposure to intellectual property claims and the costs of intellectual property litigation, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, dependence on third-party distributors in international markets, doing business in international markets, the mix of revenues between products we manufacture and sell in the United States, products we sell internationally and sales of purchased finished goods, the availability of third party reimbursement, actions by the FDA related to our products, and the loss of key vendors.